MedTrace Logo

Survival Outcomes of Residual Disease in Triple-Negative Breast Cancer

NCT07714382 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-07-20

No results posted yet for this study

Summary

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with a poor prognosis. Although neoadjuvant therapy improves outcomes in patients who achieve a pathological complete response, the presence of residual disease after treatment remains associated with an increased risk of recurrence and death. This retrospective cohort study aims to evaluate the survival outcomes of patients with residual disease following neoadjuvant therapy for TNBC and to assess the association between clinicopathological characteristics and survival outcomes, including disease-free survival and overall survival

Conditions

  • Triple-Negative Breast Cancer (TNBC)

Interventions

PROCEDURE

Chemo-radiotherapy alone

Chemo and radiotherapy before surgery

OTHER

Not applicable- observational study

Not applicable. This is a retrospective observational cohort study. No study intervention is administered. Data will be collected retrospectively from patients' medical records, and all treatments were provided as part of routine clinical care.

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2026-06-01
Completion
2026-07-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07714382 on ClinicalTrials.gov